209 related articles for article (PubMed ID: 29178334)
1. Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma.
Eriksson JA; Wanka C; Burger MC; Urban H; Hartel I; von Renesse J; Harter PN; Mittelbronn M; Steinbach JP; Rieger J
J Neurochem; 2018 Feb; 144(4):421-430. PubMed ID: 29178334
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose.
Maher JC; Wangpaichitr M; Savaraj N; Kurtoglu M; Lampidis TJ
Mol Cancer Ther; 2007 Feb; 6(2):732-41. PubMed ID: 17308069
[TBL] [Abstract][Full Text] [Related]
3. Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation.
Suganuma K; Miwa H; Imai N; Shikami M; Gotou M; Goto M; Mizuno S; Takahashi M; Yamamoto H; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Nitta M
Leuk Lymphoma; 2010 Nov; 51(11):2112-9. PubMed ID: 20860495
[TBL] [Abstract][Full Text] [Related]
4. Nodal regulates energy metabolism in glioma cells by inducing expression of hypoxia-inducible factor 1α.
Lai JH; Jan HJ; Liu LW; Lee CC; Wang SG; Hueng DY; Cheng YY; Lee HM; Ma HI
Neuro Oncol; 2013 Oct; 15(10):1330-41. PubMed ID: 23911596
[TBL] [Abstract][Full Text] [Related]
5. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitization of tumor cells to glycolytic inhibitors.
Liu H; Hu YP; Savaraj N; Priebe W; Lampidis TJ
Biochemistry; 2001 May; 40(18):5542-7. PubMed ID: 11331019
[TBL] [Abstract][Full Text] [Related]
7. Short-term exposure of multicellular tumor spheroids of a human glioma cell line to the glycolytic inhibitor 2-deoxy-D-glucose is more toxic than continuous exposure.
Khaitan D; Chandna S; Dwarakanath SB
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S67-73. PubMed ID: 20009299
[TBL] [Abstract][Full Text] [Related]
8. Reversed metabolic reprogramming as a measure of cancer treatment efficacy in rat C6 glioma model.
Datta K; Lauritzen MH; Merchant M; Jang T; Liu SC; Hurd R; Recht L; Spielman DM
PLoS One; 2019; 14(12):e0225313. PubMed ID: 31830049
[TBL] [Abstract][Full Text] [Related]
9. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.
Kuang R; Jahangiri A; Mascharak S; Nguyen A; Chandra A; Flanigan PM; Yagnik G; Wagner JR; De Lay M; Carrera D; Castro BA; Hayes J; Sidorov M; Garcia JLI; Eriksson P; Ronen S; Phillips J; Molinaro A; Koliwad S; Aghi MK
JCI Insight; 2017 Jan; 2(2):e88815. PubMed ID: 28138554
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Anticancer Action of Lysosomal Membrane Permeabilization and Glycolysis Inhibition.
Kosic M; Arsikin-Csordas K; Paunovic V; Firestone RA; Ristic B; Mircic A; Petricevic S; Bosnjak M; Zogovic N; Mandic M; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
J Biol Chem; 2016 Oct; 291(44):22936-22948. PubMed ID: 27587392
[TBL] [Abstract][Full Text] [Related]
11. Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.
Wu HB; Yang S; Weng HY; Chen Q; Zhao XL; Fu WJ; Niu Q; Ping YF; Wang JM; Zhang X; Yao XH; Bian XW
Autophagy; 2017 Sep; 13(9):1528-1542. PubMed ID: 28812437
[TBL] [Abstract][Full Text] [Related]
12. The Acidic Brain-Glycolytic Switch in the Microenvironment of Malignant Glioma.
Reuss AM; Groos D; Buchfelder M; Savaskan N
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073734
[TBL] [Abstract][Full Text] [Related]
13. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo.
Sottnik JL; Lori JC; Rose BJ; Thamm DH
Clin Exp Metastasis; 2011 Dec; 28(8):865-75. PubMed ID: 21842413
[TBL] [Abstract][Full Text] [Related]
14. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.
Chirasani SR; Leukel P; Gottfried E; Hochrein J; Stadler K; Neumann B; Oefner PJ; Gronwald W; Bogdahn U; Hau P; Kreutz M; Grauer OM
Int J Cancer; 2013 Feb; 132(4):843-53. PubMed ID: 22752934
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept.
Yuen CA; Asuthkar S; Guda MR; Tsung AJ; Velpula KK
CNS Oncol; 2016; 5(2):101-8. PubMed ID: 26997129
[TBL] [Abstract][Full Text] [Related]
16. Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting.
Hamans B; Navis AC; Wright A; Wesseling P; Heerschap A; Leenders W
Neuro Oncol; 2013 Dec; 15(12):1615-24. PubMed ID: 24158109
[TBL] [Abstract][Full Text] [Related]
17. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
18. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
20. Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model.
Shibao S; Minami N; Koike N; Fukui N; Yoshida K; Saya H; Sampetrean O
Neuro Oncol; 2018 Feb; 20(3):343-354. PubMed ID: 29016888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
